Standards; Pharmaceutical/API Drug Impurities/Metabolites;
Nonsedating-type histamine H1-receptor antagonist. Potential for combination therapy with antivancer drugs such as doxorubicin in resistant leukemia. Antihistaminic.
Wauquier, A., et al.: Eur. J. Pharmacol., 72, 245 (1981), Laduron, P.M., et al.: Mol. Pharmacol., 21, 294 (1982), Richards, D.M., et al.: Drugs, 28, 38 (1984), Al-Obaid, A.M., et al.: Anal. Profiles Drug Subs., 20, 173 (1991), Ishikawa, M., et al.: Biol. Pharm. Bull., 23, 112 (2000),
400-821-0725
沪ICP备17019645号
